CD8A and neoplasm: The presence of CD8+ T cells within the tumor microenvironment (TME) or the invasive margin of the tumor, as well as the expression of PD-L1, have emerged to be the most powerful predictors for clinical outcome in response to checkpoint inhibition [21,22].